価格表

在庫・価格 : 2024年04月24日 08時45分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
FGF-19, Human, ELISA Kit(96well) <Fibroblast Growth Factor-19, ELISA Kit>
データシート
RD191107200R BLMバイオベンダー ラボラトリー
BioVendor Laboratory Medicine, Inc.
1 kit ¥108,000
(未発注)
追加

在庫・価格 : 2024年04月24日 08時45分 現在

FGF-19, Human, ELISA Kit(96well) <Fibroblast Growth Factor-19, ELISA Kit>

  • 商品コード:RD191107200R
  • メーカー:BLM
  • 包装:1kit
  • 価格: ¥108,000
  • 在庫:無(未発注)
使用文献
No. 文献情報 備考 参照
1 Dost叩lov叩 I et al. Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J. Clin. Endocrinol. Metab. 2008 Sep;93(9):3627-32
Dost叩lov叩 I et al
2008/01/01
Species: Human, Applications: Serum,Plasma-EDTA,Plasma-Heparin,Plasma-Citrate PubMed
2 Bu転ga M et al. Effects of the intragastric balloon MedSil on weight loss, fat tissue, lipid metabolism, and hormones involved in energy balance. Obes Surg 2014 Jun;24(6):909-15
Bu転ga M et al
2014/01/01
PubMed
3 Eren F et al. Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease. Clin. Biochem. 2012 Jun;45(9):655-8
Eren F et al
2012/01/01
PubMed
4 Gallego-Escuredo JM et al. Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients. Int J Obes (Lond) 2015 Jan;39(1):121-9
Gallego-Escuredo JM et al
2015/01/01
PubMed
5 Gadaleta RM et al. Suppression of Hepatic Bile Acid Synthesis by a non-tumorigenic FGF19 analogue Protects Mice from Fibrosis and Hepatocarcinogenesis. Sci Rep 2018 Nov;8(1):17210
Gadaleta RM et al
2018/01/01
PubMed
6 Lee KJ et al. Expression of Fibroblast Growth Factor 21 and &#x3B2;-Klotho Regulates Hepatic Fibrosis through the Nuclear Factor-&#x3BA;B and c-Jun N-Terminal Kinase Pathways. Gut Liver 2018 07;12(4):449-456
Lee KJ et al
2018/01/01
PubMed
7 Li Z et al. Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis. PLoS ONE 2017;12(6):e0178580
Li Z et al
2017/01/01
PubMed
8 Nielsen S et al. Chenodeoxycholic acid stimulates glucagon-like peptide-1 secretion in patients after Roux-en-Y gastric bypass. Physiol Rep 2017 Feb;5(3)
Nielsen S et al
2017/01/01
PubMed
9 van de Wiel SMW et al. Intestinal Farnesoid X Receptor Activation by Pharmacologic Inhibition of the Organic Solute Transporter &#x3B1;-&#x3B2;. Cell Mol Gastroenterol Hepatol 2018 Mar;5(3):223-237
van de Wiel SMW et al
2018/01/01
PubMed
10 Zhou M et al. Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15. J. Hepatol. 2017 06;66(6):1182-1192
Zhou M et al
2017/01/01
PubMed
11 Z旦hrer E et al. Efficacy of docosahexaenoic acid-choline-vitamin E in paediatric NASH: a randomized controlled clinical trial. Appl Physiol Nutr Metab 2017 Sep;42(9):948-954
Z旦hrer E et al
2017/01/01
PubMed
12 Zhou M et al. Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis. J. Lipid Res. 2019 Mar;60(3):550-565
Zhou M et al
2019/01/01
PubMed
13 Zhou M et al. Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis. Nat Commun 2017 05;8:15433
Zhou M et al
2017/01/01
PubMed
14 Gadaleta RM et al. Fibroblast Growth Factor 19 modulates intestinal microbiota and inflammation in presence of Farnesoid X Receptor. EBioMedicine 2020 Apr;54:102719
Gadaleta RM et al
2020/01/01
PubMed
15 Mor坦n-Ros S et al. FGF15/19 is required for adipose tissue plasticity in response to thermogenic adaptations. Mol Metab 2021 Jan;43:101113
Mor坦n-Ros S et al
2021/01/01
PubMed
  • No.: 1
  • 文献情報:
    Dost叩lov叩 I et al. Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J. Clin. Endocrinol. Metab. 2008 Sep;93(9):3627-32
    Dost叩lov叩 I et al
    2008/01/01
  • 備考:
    Species: Human, Applications: Serum,Plasma-EDTA,Plasma-Heparin,Plasma-Citrate
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Bu転ga M et al. Effects of the intragastric balloon MedSil on weight loss, fat tissue, lipid metabolism, and hormones involved in energy balance. Obes Surg 2014 Jun;24(6):909-15
    Bu転ga M et al
    2014/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Eren F et al. Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease. Clin. Biochem. 2012 Jun;45(9):655-8
    Eren F et al
    2012/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Gallego-Escuredo JM et al. Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients. Int J Obes (Lond) 2015 Jan;39(1):121-9
    Gallego-Escuredo JM et al
    2015/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Gadaleta RM et al. Suppression of Hepatic Bile Acid Synthesis by a non-tumorigenic FGF19 analogue Protects Mice from Fibrosis and Hepatocarcinogenesis. Sci Rep 2018 Nov;8(1):17210
    Gadaleta RM et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Lee KJ et al. Expression of Fibroblast Growth Factor 21 and &#x3B2;-Klotho Regulates Hepatic Fibrosis through the Nuclear Factor-&#x3BA;B and c-Jun N-Terminal Kinase Pathways. Gut Liver 2018 07;12(4):449-456
    Lee KJ et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Li Z et al. Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis. PLoS ONE 2017;12(6):e0178580
    Li Z et al
    2017/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 8
  • 文献情報:
    Nielsen S et al. Chenodeoxycholic acid stimulates glucagon-like peptide-1 secretion in patients after Roux-en-Y gastric bypass. Physiol Rep 2017 Feb;5(3)
    Nielsen S et al
    2017/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 9
  • 文献情報:
    van de Wiel SMW et al. Intestinal Farnesoid X Receptor Activation by Pharmacologic Inhibition of the Organic Solute Transporter &#x3B1;-&#x3B2;. Cell Mol Gastroenterol Hepatol 2018 Mar;5(3):223-237
    van de Wiel SMW et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 10
  • 文献情報:
    Zhou M et al. Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15. J. Hepatol. 2017 06;66(6):1182-1192
    Zhou M et al
    2017/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 11
  • 文献情報:
    Z旦hrer E et al. Efficacy of docosahexaenoic acid-choline-vitamin E in paediatric NASH: a randomized controlled clinical trial. Appl Physiol Nutr Metab 2017 Sep;42(9):948-954
    Z旦hrer E et al
    2017/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 12
  • 文献情報:
    Zhou M et al. Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis. J. Lipid Res. 2019 Mar;60(3):550-565
    Zhou M et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 13
  • 文献情報:
    Zhou M et al. Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis. Nat Commun 2017 05;8:15433
    Zhou M et al
    2017/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 14
  • 文献情報:
    Gadaleta RM et al. Fibroblast Growth Factor 19 modulates intestinal microbiota and inflammation in presence of Farnesoid X Receptor. EBioMedicine 2020 Apr;54:102719
    Gadaleta RM et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 15
  • 文献情報:
    Mor坦n-Ros S et al. FGF15/19 is required for adipose tissue plasticity in response to thermogenic adaptations. Mol Metab 2021 Jan;43:101113
    Mor坦n-Ros S et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed